Quarterly Result14 Aug 2026, 04:21 pm
Sanjivani Parenteral Q1 FY27: Revenue ₹239.90 Mn, PAT ₹24.91 Mn
AI Summary
Sanjivani Parenteral Limited announced its Unaudited Financial Results for Q1 FY27, reporting a Total Income of ₹239.90 Mn, a 33.81% year-on-year increase. EBITDA grew by 61.04% to ₹43.21 Mn, with EBITDA margin improving by 305 basis points to 18.01%. Profit After Tax (PAT) rose by 43.94% to ₹24.91 Mn, and PAT margin improved to 10.38%. The company saw strong performance in its Injectables segment and significant contribution from exports, which accounted for 90.50% of revenue. The Chairman & Managing Director highlighted operational efficiencies and a positive start to the fiscal year.
Key Highlights
- Q1 FY27 Total Income up 33.81% YoY to ₹239.90 Mn.
- EBITDA surged 61.04% YoY to ₹43.21 Mn, margin improved.
- PAT increased 43.94% YoY to ₹24.91 Mn, margin improved.
- Exports contributed 90.50% of revenue, growing 33.49% YoY.
- Injectables segment leads revenue contribution at 56.59%.
Price Impact
More from SANJIVIN